BP-C1 in the treatment of patients with stage IV breast cancer: a randomized, double-blind, placebo-controlled multicenter study and an additional open-label treatment phase

Stig Larsen1 Department of Controlled Clinical Trials and Biostatistics, Centre for Epidemiology and Biostatistics, University of Life Science, Oslo, Norway

Kritiya Butthongkomvong2 Udonthani Cancer Hospital, Udonthani, Thailand

Alexey Manikhas3 Department of Oncology, City Clinical Oncology, Dispensary, St Petersburg, Russia

Ekaterina Trishkina4 Department of Oncology, Leningrad Regional Oncology Centre, St Petersburg, Russia

Elena Poddubuskaya5 Department of Oncology, Unit of Russian Academy of Medical Science, Moscow, Russia

Marina Matrosova6 Department of Oncology, N Novgorod Regional Oncology Dispensary, Novgorod, Russia

Vichien Srimuninnimit7 Division of Medical Oncology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand

Steen Lindkær-Jensen8 Department of Surgery and Cancer, Imperial College, Hammersmith Hospital, London, UKCorrespondence[email protected]

show all

Citations (4)

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Kritiya Butthongkomvong, Nilubol Raunroadroong, Sirikul Sorrarichingchai, Isaraporn Sangsaikae, Vichien Srimuninnimit, Henrik Harling & Stig Larsen. (2019) Efficacy and tolerability of BP-C1 in metastatic breast cancer: a Phase II, randomized, double-blind, and placebo-controlled Thai multi-center study. Breast Cancer: Targets and Therapy 11, pages 43-51.
Read now

Steen Lindkær-Jensen, Stig Larsen, Nina Habib-Lindkær-Jensen & Hans E Fagertun. (2015) Positive effects on hematological and biochemical imbalances in patients with metastatic breast cancer stage IV, of BP-C1, a new anticancer substance. Drug Design, Development and Therapy 9, pages 1481-1490.
Read now

Articles from other publishers (2)

Elena I. Fedoros, Alexey A. Orlov, Alexander Zherebker, Ekaterina A. Gubareva, Mikhail A. Maydin, Andrey I. Konstantinov, Konstantin A. Krasnov, Ruben N. Karapetian, Ekaterina I. Izotova, Sergey E. Pigarev, Andrey V. Panchenko, Margarita L. Tyndyk, Dmitry I. Osolodkin, Evgeny N. Nikolaev, Irina V. Perminova & Vladimir N. Anisimov. (2018) Novel water-soluble lignin derivative BP-Cx-1: identification of components and screening of potential targets in silico and in vitro . Oncotarget 9:26, pages 18578-18593.
Crossref

Richard J. Browning, Philip James Thomas Reardon, Maryam Parhizkar, R. Barbara Pedley, Mohan Edirisinghe, Jonathan C. Knowles & Eleanor Stride. (2017) Drug Delivery Strategies for Platinum-Based Chemotherapy. ACS Nano 11:9, pages 8560-8578.
Crossref

BP-C1 in the treatment of patients with stage IV breast cancer: a randomized, double-blind, placebo-controlled multicenter study and an additional open-label treatment phase

Articles from other publishers (2)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

BP-C1 in the treatment of patients with stage IV breast cancer: a randomized, double-blind, placebo-controlled multicenter study and an additional open-label treatment phase

Citations (4)

Read on this site (2)

Articles from other publishers (2)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date